Trial reportAmerican journal of respiratory and critical care medicine2020
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.
Erratum issuedOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph
Trial report in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
28.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 265 citations in OpenAlex.
- Quality of life among obstructive sleep apnoea patients: a systematic review and meta-analysis of EQ-5D studies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Efficacy of Pitolisant 20 mg in Reducing Excessive Daytime Sleepiness and Fatigue in Patients with Obstructive Sleep Apnoea Syndrome: An Individual Patient Data Meta-analysis.Clinical drug investigation · 2022Pooled it
- European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea.European respiratory review : an official journal of the European Respiratory Society · 2021Guideline
- Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.Journal of sleep research · 2025Trial
- Test-retest reliability of the Epworth Sleepiness Scale in clinical trial settings.Journal of sleep research · 2022Trial
- Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Trial
- Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021Trial
- Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The development of a digital pathway for the assessment of residual excessive daytime sleepiness in obstructive sleep apnoea: a service evaluation.ERJ open research · 2026Article
- The Role of Pharmacotherapy for Excessive Daytime Sleepiness in OSA: A Changing Landscape?CHEST pulmonary · 2026Review
- Article
- Causal effects of modifiable risk factors on obstructive sleep apnea: A Mendelian randomization study and validation study.Medicine · 2026Article
- Obstructive Sleep Apnoea Treatments-Where Are We Now?Respirology (Carlton, Vic.) · 2025Article
- Efficacy of armodafinil in moderate to severe obstructive sleep apnea patients with excessive daytime sleepiness after suboptimal usage of continuous positive airway pressure treatment: a prospective study.Sleep & breathing = Schlaf & Atmung · 2025Article
- Personalized endpoints in Prader-Willi syndrome: a case study with goal attainment scaling.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- Article
- Redefining telemedicine in obstructive sleep apnea management through artificial intelligence.Frontiers in sleep · 2025Article
- Acute hypobaric hypoxia attenuates the anti-fatigue effects of pitolisant by downregulating the expression of organic cation transporter 1 and P-glycoprotein.Frontiers in pharmacology · 2025Article
- Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management.Sleep medicine: X · 2024Review
- Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysis.EClinicalMedicine · 2024Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
15 authors at 8 institutions in 5 countries.
Yves DauvilliersNational Reference Center for Narcolepsy, Sleep and Wake Unit, Department of Neurology, Gui-de-Chauliac Hospital, Montpellier University Hospital, Montpellier, France.ORCID 0000-0003-0683-6506
Johan VerbraeckenMultidisciplinary Sleep Disorders Center, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.
Markku PartinenHelsinki Sleep Clinic, Vitalmed Research Center, Helsinki, Finland.
Jan HednerSleep and Vigilance Laboratory, Department of Internal Medicine, University of Göteborg, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden.
Tarja SaaresrantaSleep Research Center, Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.
Ognian GeorgievPulmonology Unit, Department of Internal Medicine, Alexandrovska Hospital Medical University, Sofia, Bulgaria.
Rumen TiholovDepartment of Internal Diseases, Sveti Ivan Rilski Multiprofile Hospital for Active Treatment, Kozloduy, Bulgaria.
Isabelle LecomteBioprojet, 30 rue Francs Bourgois, Paris, France.
Renaud TamisierHypoxia-Physiopathology (HP2) Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France; and.
Patrick LévyHypoxia-Physiopathology (HP2) Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France; and.
Catherine Scart-GresBioprojet, 30 rue Francs Bourgois, Paris, France.
Jeanne-Marie LecomteBioprojet, 30 rue Francs Bourgois, Paris, France.
Jean-Charles SchwartzBioprojet, 30 rue Francs Bourgois, Paris, France.
Jean-Louis PépinHypoxia-Physiopathology (HP2) Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France; and.
HAROSA II Study Group collaborators
Bioprojet (France) · FRInserm · FRAlexandrovska Hospital · BGSahlgrenska University Hospital · SEUniversity Multipurpose Hospital for Active Treatment "Sveti Georgi" · BGUniversity of Antwerp · BEUniversity of Helsinki · FIUniversity of Turku · FI
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedContinuous Positive Airway PressureDisorders of Excessive SomnolenceDouble-Blind MethodFemaleHumansMaleMiddle AgedPiperidinesReceptors, Histamine H3Self ReportSleep Apnea, ObstructiveSurveys and QuestionnairesTreatment OutcomePiperidinespitolisantReceptors, Histamine H3continuous positive airway pressureexcessive daytime sleepinessobstructive sleep apneapitolisant
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.